# A Study of Capecitabine (Xeloda) in Participants With Locally Advanced or Metastatic Pancreatic Cancer

> **NCT02565641** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 63 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02565641
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2006-09
- **Final completion:** 2006-09
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02565641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02565641, "A Study of Capecitabine (Xeloda) in Participants With Locally Advanced or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02565641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*